A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes (Olaparib Expanded) identifier:
NCT03344965 (

Study Contact Information:

For additional information, please contact the coordinating center by email.  

 About the Study

This study is no longer recruiting people. 

DFCI 17-428 (Olaparib Expanded) is a study looking at whether the drug Olaparib is effective treatment for people with certain types of metastatic breast cancer. Olaparib belongs to a class of drugs known as PARP inhibitors. PARP inhibitors are particularly effective for treating tumors in people with an inherited BRCA mutation. This study is looking at whether olaparib is also effective for treating metastatic breast cancer in people who do not have an inherited BRCA mutation.

The study is looking at olaparib to treat metastatic breast cancer in two specific groups of patients who have tested negative for a BRCA mutation:

Type of Study

This is a Phase 2, non-randomized 2-arm, open-label study evaluating olaparib in metastatic breast cancer patients with either a non-BRCA germline (inherited) mutation or a somatic (acquired) mutation found in the blood or tumor tissue. Participants with a BRCA1 or BRCA2 germline mutation are not eligible for this study, as Olaparib is already FDA approved for these patients. Response to treatment will be analyzed by periodic assessments of the tumor by CT scans.

What the Study Entails

Study Sites

For a full list of open sites, see the listing.

Principal Investigator

The study PI is Nadine Tung, MD: 617-667-1962 or by email

This Study is Open To:

This study is no longer recruiting people. 

This Study is Not Open To:

This study is no longer recruiting people. 


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.